Monika Lusky, PhD, has more than 30 years’ experience in studying, optimizing and developing viral-based therapies. As a Director and Senior program leader at Transgene, she coordinates the clinical development of two clinical stage immunotherapies: Pexa-Vec and TG4001, with a particular focus on combinations with immune checkpoint inhibitors. Previously, Monika was Senior Scientific Analyst and Head of the adenovirology laboratory at Transgene, where she acquired an extensive and in-depth knowledge of viral-based therapies. She was an Associate Professor within the Department of Microbiology at Cornell University Medical College (NY, USA). Monika Lusky has a PhD in Molecular Biology and Genetics. She authored more than 50 articles published in international scientific journals.